CA2423744C — Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
Assigned to Topotarget UK Ltd · Expires 2012-04-03 · 14y expired
What this patent protects
This invention pertains to certain active hydroxamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: -S(=O)2NR1- and -NR1S(=O)2-; R1 i…
USPTO Abstract
This invention pertains to certain active hydroxamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: -S(=O)2NR1- and -NR1S(=O)2-; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is -S(=O)2NR1-, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
Drugs covered by this patent
- Beleodaq (belinostat) · Acrotech Biopharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.